CClinicalTrials.gg
RecruitingNCT04890730Updated Nov 27, 2023

Non-invasive Method for Predicting the Presence of Gastroesophageal Varices in Patients With Cirrhosis-a Prospective, Multicenter Trial

An observational study in Gastroesophageal Varices; Decompensation Event, sponsored by Nanfang Hospital, Southern Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-11-27.

Sponsored by Nanfang Hospital, Southern Medical University · Observational

From the registry’s dates

  • Primary completion was expected by Oct 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Nov 2020; still recruiting 5 years 11 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
992
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Gastroesophageal varices are a complication of portal hypertension in cirrhosis.Endoscopy is an unsatisfactory screening test.In this prospective clinical study,we will enroll patients with cirrhosis of various causes, all of whom undergo laboratory tests, elastography, and serum proteomic differential protein testing, including liver elastography (LSM) and spleen elastography (SSM). Baveno VI or expanded BavenoVI criteria are validated by comparing patients' LSM and PLT. LSM, SSM, serum differential protein, platelet count, and EGD data to evaluate the clinical value of SSM and differential proteins in excluding cirrhosis with varices. At the same time, a new predictive model of variceal varices will be established to evaluate the diagnostic value of SSM and differential protein for esophagogastric varices, and a non-invasive method for reliably predicting and evaluating cirrhosis with esophageal varices will be found. And each patient will be followed up every 6 months to 1 year, and the outcome event will be recorded.

Read the detailed description

Gastroesophageal varices are a complication of portal hypertension in cirrhosis.Endoscopy is invasive method as an unsatisfactory screening test.In this prospective clinical study, we will enroll patients with cirrhosis of various causes, all of patients whom undergo laboratory tests, elastography, and serum proteomic differential protein testing, including LSM and SSM. Baveno VI or expanded BavenoVI criteria are validated by comparing patients' LSM and PLT. LSM,SSM, serum differential protein, platelet count, and EGD data to evaluate the clinical value of SSM and differential proteins in excluding cirrhosis with varices. At the same time, based on SSM and serum differential protein, a new predictive model of variceal varices will be established to evaluate the diagnostic value of SSM and differential protein for esophagogastric varices, and a non-invasive method for reliably predicting and evaluating cirrhosis with esophageal varices will be found. And each patient will be followed up every 6 months to 1 year, and the outcome event will be recorded.

02

Conditions studied

  • Gastroesophageal Varices; Decompensation Event
03

In context

Esophageal and Gastric Varices

169 studies on the registry are indexed under Esophageal and Gastric Varices; 41 are open to participants now.

This study's planned enrollment of 992 is above the median of 130 across 51 observational studies indexed under Esophageal and Gastric Varices.

Browse Esophageal and Gastric Varices studies →

Lead sponsor

Nanfang Hospital, Southern Medical University is the lead sponsor of 480 studies on the registry; 212 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients who come to the center to see a doctor who meet the enrollment criteria and agree to participate in the study

Inclusion criteria

    1. The age ranged from 18 to 80 years. 2. Clinical or pathological diagnosis of cirrhosis; 3. Electronic gastroscopy is planned; 4. To agree and sign the informed consent;

Exclusion criteria

Exclusion Criteria:

  • 1.Orthotopic liver transplantation patients; 2. Patients who have undergone transjugular intrahepatic portosystemic shunt (TIPS),or previous surgical shunt; 3. Pregnant women; 4. Neurological or psychiatric disorders;
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
992 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Southern Medical University of Nanfang Hospital

    Southern Medical University of Nanfang Hospital

    Other: Esophagogastroduodenoscopies

  • Tongji Hospital Affiliated to Tongji University

    Tongji Hospital Affiliated to Tongji University

    Other: Esophagogastroduodenoscopies

  • The Second Affiliated Hospital Of Nanchang University

    The Second Affiliated Hospital Of Nanchang University

    Other: Esophagogastroduodenoscopies

Interventions

  • OtherEsophagogastroduodenoscopies

    Each enrolled patient needs to undergo Esophagogastroduodenoscopies and elastography

06

What researchers measure

Primary outcomes

  1. Incidence of high-risk esophageal varices

    Incidence of high-risk esophageal varices

    Time frame: 4 years

Secondary outcomes

  1. Incidence of hemorrhagic events

    Incidence of hemorrhagic events

    Time frame: 4 years

  2. Incidence of Clinical decompensation events and deaths

    Incidence of Clinical decompensation events and deaths

    Time frame: 4 years

07

Study locations

1 of 1 sites recruiting
  • Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University
    Guangzhou, China
    Recruiting
08

References and documents

Publications

  • Zhang X, Song J, Zhang Y, Wen B, Dai L, Xi R, Wu Q, Li Y, Luo X, Lan X, He Q, Luo W, Lai Q, Ji Y, Zhou L, Qi T, Liu M, Zhou F, Wen W, Li H, Liu Z, Chen Y, Zhu Y, Li J, Huang J, Cheng X, Tu M, Hou J, Wang H, Chen J. Baveno VII algorithm outperformed other models in ruling out high-risk varices in individuals with HBV-related cirrhosis. J Hepatol. 2023 Mar;78(3):574-583. doi: 10.1016/j.jhep.2022.10.030. Epub 2022 Nov 7. PubMed 36356684 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04890730
Lead sponsor
Nanfang Hospital, Southern Medical University
Responsible party
Sponsor
First posted
May 18, 2021
Start date
Nov 1, 2020
Primary completion
Oct 30, 2024 (estimated)
Completion
Oct 30, 2024 (estimated)
Last update
Nov 27, 2023

Study contacts

Jinjun Chen, PHd
Contact
chjj@smu.edu.cn
8618588531001
Haiyu Wang
Contact
375612668@qq.com
15602203979

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion